{"id":42585,"date":"2023-11-10T21:48:44","date_gmt":"2023-11-10T21:48:44","guid":{"rendered":"https:\/?p=42585"},"modified":"2023-11-10T21:48:44","modified_gmt":"2023-11-10T21:48:44","slug":"biogen-biib-morgan-stanley-raised-the-target-to-373-from-361","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/biogen-biib-morgan-stanley-raised-the-target-to-373-from-361\/","title":{"rendered":"Biogen (BIIB) Morgan Stanley raised the target to $373 from $361"},"content":{"rendered":"<h2>Analyst Ratings Coverage<\/h2>\n<div class=\"group w-full text-token-text-primary border-b border-black\/10 gizmo:border-0 dark:border-gray-900\/50 gizmo:dark:border-0 bg-gray-50 gizmo:bg-transparent dark:bg-[#444654] gizmo:dark:bg-transparent\" data-testid=\"conversation-turn-31\">\n<div class=\"p-4 gizmo:py-2 justify-center text-base md:gap-6 md:py-6 m-auto\">\n<div class=\"flex flex-1 gap-4 text-base mx-auto md:gap-6 gizmo:gap-3 gizmo:md:px-5 gizmo:lg:px-1 gizmo:xl:px-5 md:max-w-2xl lg:max-w-[38rem] gizmo:md:max-w-3xl gizmo:lg:max-w-[40rem] gizmo:xl:max-w-[48rem] xl:max-w-3xl }\">\n<div class=\"relative flex w-[calc(100%-50px)] flex-col gizmo:w-full lg:w-[calc(100%-115px)] agent-turn\">\n<div class=\"flex-col gap-1 md:gap-3\">\n<div class=\"flex flex-grow flex-col max-w-full gap-3 gizmo:gap-0\">\n<div class=\"min-h-[20px] text-message peer flex flex-col items-start gap-3 whitespace-pre-wrap break-words peer-[.text-message]:mt-5 overflow-x-auto\" data-message-author-role=\"assistant\" data-message-id=\"41b2f8ba-1510-43cc-9994-549bc891421c\">\n<div class=\"markdown prose w-full break-words dark:prose-invert light\">\n<p>Morgan Stanley &amp; Co. <a href=\"https:\/\/www.stocktargetadvisor.com\/Analyst-Ranking\/Morgan%20Stanley%20%26%20Co.\">(Rank#1)<\/a> has recently issued a\u00a0 research report,\u00a0 maintaining its &#8220;Overweight&#8221; rating on Biogen&#8217;s stock, signaling a positive outlook on its performance. Morgan Stanley also made a revision in the target price from USD 361 to USD 373, indicating a bullish forecast.<\/p>\n<p><!-- STA Widget BEGIN --><\/p>\n<div>\n<div class=\"sta-analyst-rating-widget-display\">\n<p><a style=\"text-decoration: none; color: #4b6db5 !important;\" href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NSD\/BIIB\" target=\"_blank\" rel=\"noopener\">BIIB Ratings<\/a> by Stock Target Advisor<\/p>\n<\/div>\n<p><script class=\"analyst-rating\" type=\"text\/javascript\" src=\"https:\/\/www.stocktargetadvisor.com\/assets\/js\/analyst_rating_widget.js\" data-symbol=\"BIIB\" data-theme=\"wt_bg_light\" data-uid=\"1732823140654ea4b90e0f9654ea4b90e0fa\" data-width=\"900\" >\n\t\t<\/script><\/p>\n<\/div>\n<h2>Biogen Stock Analysis<\/h2>\n<p><strong>Analyzing Biogen Inc: Analyst Forecasts, Ratings, and Stock Performance<\/strong><\/p>\n<p>Biogen Inc, a prominent biotechnology company, has garnered attention from analysts, investors, and Stock Target Advisor. This comprehensive analysis delves into the forecasts, ratings, and stock performance to provide insights into the current sentiments surrounding Biogen Inc.<\/p>\n<p><strong>Analyst Forecasts:<\/strong> According to the projections of 22 analysts, the average target price for Biogen Inc&#8217;s stock over the next 12 months is USD 327.90. This consensus target reflects the collective wisdom of financial experts, considering factors such as the company&#8217;s financial health, product pipeline, and industry dynamics. The substantial target price suggests a positive outlook on Biogen&#8217;s future performance.<\/p>\n<p><strong>Analyst Ratings:<\/strong> The average analyst rating for Biogen Inc is classified as &#8220;Strong Buy.&#8221; This rating indicates a high level of confidence among analysts that the stock is poised for significant growth. A &#8220;Strong Buy&#8221; rating often implies that analysts believe the stock will outperform its peers and the broader market.<\/p>\n<p><strong>Stock Target Advisor Analysis:<\/strong> <a href=\"https:\/\/www.stocktargetadvisor.com\/\">Stock Target Advisor<\/a>, an independent analysis platform, presents its own evaluation of Biogen Inc, categorizing it as &#8220;Neutral.&#8221; This stance is derived from a balance of 6 positive signals and 7 negative signals identified by the platform. These signals incorporate various factors such as financial metrics, market trends, and external influences that may impact the stock.<\/p>\n<p><strong>Recent Stock Performance:<\/strong> As of the last closing, Biogen Inc&#8217;s stock was valued at USD 224.65. Examining recent performance:<\/p>\n<ul>\n<li>Over the past week, the stock price decreased by -7.12%.<\/li>\n<li>Over the past month, the stock price declined by -14.97%.<\/li>\n<li>Over the last year, the stock price exhibited a decrease of -20.42%.<\/li>\n<\/ul>\n<p><strong>Interpreting the Data:<\/strong><\/p>\n<ol>\n<li><strong>Divergence in Views:<\/strong> The significant variance between the average analyst target price and the recent stock performance suggests differing perspectives in the market. While analysts maintain a positive stance with a &#8220;Strong Buy&#8221; rating and a high target price, Stock Target Advisor&#8217;s &#8220;Neutral&#8221; analysis introduces a more cautious viewpoint.<\/li>\n<li><strong>Potential for Upside:<\/strong> The high target price implies the potential for substantial upside, making Biogen Inc an attractive prospect for investors seeking growth opportunities in the biotechnology sector.<\/li>\n<li><strong>Mixed Signals:<\/strong> The &#8220;Neutral&#8221; analysis from Stock Target Advisor underscores the complexity of assessing Biogen&#8217;s overall outlook. A balance of positive and negative signals suggests a nuanced evaluation, considering both the strengths and challenges facing the company.<\/li>\n<\/ol>\n<p><strong>Investor Considerations:<\/strong><\/p>\n<ol>\n<li><strong>Thorough Due Diligence:<\/strong> Investors should conduct thorough research, delving into Biogen&#8217;s financial reports, drug pipeline, and recent developments to understand the basis for the &#8220;Strong Buy&#8221; rating and the &#8220;Neutral&#8221; analysis.<\/li>\n<li><strong>Risk Assessment:<\/strong> Given the mixed signals, investors should carefully consider potential risks, including regulatory challenges, competition, and industry dynamics that may impact Biogen Inc&#8217;s future performance.<\/li>\n<li><strong>Market Dynamics:<\/strong> Biotechnology stocks are often influenced by regulatory approvals, clinical trial outcomes, and market sentiment. Staying informed about these dynamics is crucial for investors.<\/li>\n<\/ol>\n<p><strong>Final Stock Analysis<\/strong><\/p>\n<p>Biogen Inc presents an interesting case with a high average analyst target price and a &#8220;Strong Buy&#8221; rating, contrasting with Stock Target Advisor&#8217;s more cautious &#8220;Neutral&#8221; analysis. Investors should approach the stock with a balanced perspective, weighing the potential for growth against the mixed signals and recent stock performance. Conducting thorough due diligence and staying informed about market dynamics will be essential for making informed investment decisions.<\/p>\n<p>&nbsp;<\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"flex justify-between empty:hidden gizmo:justify-start gizmo:gap-3 lg:block gizmo:lg:flex\">\n<div class=\"text-gray-400 flex self-end lg:self-center justify-center gizmo:lg:justify-start mt-2 gizmo:mt-0 visible lg:gap-1 lg:absolute lg:top-0 lg:translate-x-full lg:right-0 lg:mt-0 lg:pl-2 gap-2 md:gap-3\">\n<p>&nbsp;<\/p>\n<div class=\"flex gap-1\"><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Analyst Ratings Coverage Morgan Stanley &amp; Co. (Rank#1) has recently issued a\u00a0 research report,\u00a0 maintaining its &#8220;Overweight&#8221; rating on Biogen&#8217;s stock, signaling a positive outlook&#8230;<\/p>\n","protected":false},"author":3,"featured_media":6318,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"image","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-42585","post","type-post","status-publish","format-image","has-post-thumbnail","hentry","category-blog","post_format-post-format-image"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v19.4 (Yoast SEO v21.4) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Biogen (BIIB) Morgan Stanley raised the target to $373 from $361 | Stock Target Advisor<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.stocktargetadvisor.com\/blog\/biogen-biib-morgan-stanley-raised-the-target-to-373-from-361\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biogen (BIIB) Morgan Stanley raised the target to $373 from $361\" \/>\n<meta property=\"og:description\" content=\"Analyst Ratings Coverage Morgan Stanley &amp; Co. (Rank#1) has recently issued a\u00a0 research report,\u00a0 maintaining its &#8220;Overweight&#8221; rating on Biogen&#8217;s stock, signaling a positive outlook...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/biogen-biib-morgan-stanley-raised-the-target-to-373-from-361\/\" \/>\n<meta property=\"og:site_name\" content=\"Stock Target Advisor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-10T21:48:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2021\/06\/biogen.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"STA Research\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:site\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"STA Research\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/biogen-biib-morgan-stanley-raised-the-target-to-373-from-361\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/biogen-biib-morgan-stanley-raised-the-target-to-373-from-361\/\"},\"author\":{\"name\":\"STA Research\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae\"},\"headline\":\"Biogen (BIIB) Morgan Stanley raised the target to $373 from $361\",\"datePublished\":\"2023-11-10T21:48:44+00:00\",\"dateModified\":\"2023-11-10T21:48:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/biogen-biib-morgan-stanley-raised-the-target-to-373-from-361\/\"},\"wordCount\":599,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"articleSection\":[\"Market News &amp; Insights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/biogen-biib-morgan-stanley-raised-the-target-to-373-from-361\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/biogen-biib-morgan-stanley-raised-the-target-to-373-from-361\/\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/biogen-biib-morgan-stanley-raised-the-target-to-373-from-361\/\",\"name\":\"Biogen (BIIB) Morgan Stanley raised the target to $373 from $361 | Stock Target Advisor\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\"},\"datePublished\":\"2023-11-10T21:48:44+00:00\",\"dateModified\":\"2023-11-10T21:48:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/biogen-biib-morgan-stanley-raised-the-target-to-373-from-361\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/biogen-biib-morgan-stanley-raised-the-target-to-373-from-361\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/biogen-biib-morgan-stanley-raised-the-target-to-373-from-361\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biogen (BIIB) Morgan Stanley raised the target to $373 from $361\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"name\":\"Stock Target Advisor\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\",\"name\":\"Stock Target Advisor\",\"alternateName\":\"STA\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"contentUrl\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"width\":\"225\",\"height\":\"225\",\"caption\":\"Stock Target Advisor\"},\"image\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\",\"https:\/\/twitter.com\/AdvisorTarget\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae\",\"name\":\"STA Research\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g\",\"caption\":\"STA Research\"},\"description\":\"STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/author\/sta-research\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biogen (BIIB) Morgan Stanley raised the target to $373 from $361 | Stock Target Advisor","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.stocktargetadvisor.com\/blog\/biogen-biib-morgan-stanley-raised-the-target-to-373-from-361\/","og_locale":"en_US","og_type":"article","og_title":"Biogen (BIIB) Morgan Stanley raised the target to $373 from $361","og_description":"Analyst Ratings Coverage Morgan Stanley &amp; Co. (Rank#1) has recently issued a\u00a0 research report,\u00a0 maintaining its &#8220;Overweight&#8221; rating on Biogen&#8217;s stock, signaling a positive outlook...","og_url":"https:\/\/www.stocktargetadvisor.com\/blog\/biogen-biib-morgan-stanley-raised-the-target-to-373-from-361\/","og_site_name":"Stock Target Advisor","article_publisher":"https:\/\/www.facebook.com\/StockTargetAdvisor\/","article_published_time":"2023-11-10T21:48:44+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2021\/06\/biogen.jpg","type":"image\/jpeg"}],"author":"STA Research","twitter_card":"summary_large_image","twitter_creator":"@AdvisorTarget","twitter_site":"@AdvisorTarget","twitter_misc":{"Written by":"STA Research","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/biogen-biib-morgan-stanley-raised-the-target-to-373-from-361\/#article","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/biogen-biib-morgan-stanley-raised-the-target-to-373-from-361\/"},"author":{"name":"STA Research","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae"},"headline":"Biogen (BIIB) Morgan Stanley raised the target to $373 from $361","datePublished":"2023-11-10T21:48:44+00:00","dateModified":"2023-11-10T21:48:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/biogen-biib-morgan-stanley-raised-the-target-to-373-from-361\/"},"wordCount":599,"commentCount":0,"publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"articleSection":["Market News &amp; Insights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.stocktargetadvisor.com\/blog\/biogen-biib-morgan-stanley-raised-the-target-to-373-from-361\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/biogen-biib-morgan-stanley-raised-the-target-to-373-from-361\/","url":"https:\/\/www.stocktargetadvisor.com\/blog\/biogen-biib-morgan-stanley-raised-the-target-to-373-from-361\/","name":"Biogen (BIIB) Morgan Stanley raised the target to $373 from $361 | Stock Target Advisor","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website"},"datePublished":"2023-11-10T21:48:44+00:00","dateModified":"2023-11-10T21:48:44+00:00","breadcrumb":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/biogen-biib-morgan-stanley-raised-the-target-to-373-from-361\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.stocktargetadvisor.com\/blog\/biogen-biib-morgan-stanley-raised-the-target-to-373-from-361\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/biogen-biib-morgan-stanley-raised-the-target-to-373-from-361\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.stocktargetadvisor.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Biogen (BIIB) Morgan Stanley raised the target to $373 from $361"}]},{"@type":"WebSite","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","name":"Stock Target Advisor","description":"","publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization","name":"Stock Target Advisor","alternateName":"STA","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/","url":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","contentUrl":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","width":"225","height":"225","caption":"Stock Target Advisor"},"image":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/StockTargetAdvisor\/","https:\/\/twitter.com\/AdvisorTarget"]},{"@type":"Person","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae","name":"STA Research","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g","caption":"STA Research"},"description":"STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.","url":"https:\/\/www.stocktargetadvisor.com\/blog\/author\/sta-research\/"}]}},"_links":{"self":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/42585","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/comments?post=42585"}],"version-history":[{"count":1,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/42585\/revisions"}],"predecessor-version":[{"id":42587,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/42585\/revisions\/42587"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media\/6318"}],"wp:attachment":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media?parent=42585"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/categories?post=42585"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/tags?post=42585"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}